A Randomized Controlled Clinical Trial of Earandadi Kwath and Kaishor Guggulu in the Management of Vatarakta

Dr. Shrikant S. Kulat ¹, Dr. Varsha P. Desai ², Dr. Hrishikesh Malavade³

1Assistant professor Department of Kaychikitsa ²Assistant professor Department of Shalakyatantra Dr Vadantatai J. Dhone Gramin Ayurved College, Patur ³Asso. Prof. & HOD, Dept. of Rachana Sharir, Sant Gajanan Maharaj Ayurved Medical College, Mahagaon.

Received: 11 March 2024 Accepted: 27 March 2024

Abstract

major Vatarakta is example of Vata vvadhi, caused to avarana pathology. The scenario of *Utthana Vatarakta* occurred owing to the margavarana pathology, which can very well be correlated with atherosclerotic peripheral arterial disease. The literature enlists a number of Guggulu prayogas in the management of Vatarakta. An additional cavernous revise was indispensable to bring out the precise outcome of these products. Keeping these visions in mind, the particular comparative study was performed with Kaishora guggulu and Amrita guggulu, which are explained in the same context. This is a single-blind comparative clinical study. The 30 patients of group A were treated with Earandadi Kwath and 30 patients of Group B patients were treated with Kaishor Guggulu. The therapeutic effect of the treatment was assessed in both the groups based on specific subjective and objective parameters. The results obtained were analyzed statistically in both the groups and the comparative effect was assessed using the unpaired "t" -test. In both the groups, a statistically significant improvement was observed in all the criteria of assessment. The outcome of the study revealed an identical therapeutic efficacy of Kaishor guggulu and Earandadi Kwath in Vatarakta.

Keywords - Vatarakta, Margavarana, Raktavahasrotas, Atherosclerosis, Peripheral Vascular Diseases

Introduction:

Vatarakta is described as Vata Shonita in Charaka Samhita, Vagbhat Samhita and Madhav Nidan. Sushruta has explained Vatarakta in Vatvyadhi.

In Vatarakta, Vata Dosha and Rakta Dhatu are Vitiated with separate etiological factors and these travels is whole body and obstructs in to the Parva

> **Author Correspondence** Dr. Shrikant S. Kulat

Dr Vadantatai J. Dhone Gramin Ayurved College, Email: shrikantkulat@gmail.com

Sandhi and symptoms starts as a Parva Sandhi Shula, Daha and Shotha in Parva Sandhi.

According to modern Vatarakta is known as Gout. It is an musculoskeletal inflammatory joint disorder in which joint becomes swollen and painful. It is a metabolic and heterogeneous disorder that results in the deposition of uric acid salts and crystals in and around joints and soft tissues or crystallization of uric acid in the urinary tract. It is debilitating disease in view of chronicity and complication. Therefore it has taken the foremost place among the joint

(108) vidyapharma.com

disorder. It continues to pose challenge to physician due to sever morbidity and crippling nature and claiming the maximum loss f human power and sometime amputation may be as a complication.

According to surveillance and present era the incidence of Vatarakta is 2-26 per 1000 population. Vatarakta shows clinically Shotha, Dhah, Shool in Parv Sandhi so to cure these the choice of Kalpa selected here is Earandadi Kwath in which 6 drug are included. Among them Earand, Bula, Guduchi etc. acts as Raktashodhak. Gokshar the risk of renal calculi Kokilaksh act, as Vatapitta Shamak. Kaishor Guggulu is a controlled drug which is commonly, used in Vatavyadi and Vatarakta.

Aim:

To study the effects of Earandadi Kwath in the management of Vatarakta.

Objectives:

- 1. To study the Ayurvedic literature available on Vatarakta.
- 2. To study the effect of Earandadi Kwath in the management of Vatarakta.
- 3. To compaire the effect of Earandadi Kwath and Kaishor Guggulu.

Study Design:

Open Randomised Controlled clinical study done. The patients were selected irrespective of sex, religion, socio-economic status. All the patients were examined by Trividh, Ashtavidha, Dashavidha pariksha. A separate case paper was designed with special consent. Follow up were taken at the interval of 15 days for 3 months.

All the aspects of trial explained to participating patients & after a written and informed consent were taken from the patientes of both groups.

Inclusion Criteria:

- 1) Patients having textual signs & symptoms of vatarakta.
- 2) Age: 20 to 60 years.
- 3) Patient were selected irrespective of religion, sex & socioeconomic status.

Exclusion Criteria:

- 1. Aamavata, (SLE, Rheumatic arthritis etc.)
- Sandhigatavata (Osteoarthritis)
- 3. Pregnancy
- 4. Any other major illness like Diabetis Mellitus, Tuberculosis, Leprosy HIV etc.
- 5. Patients below 20 years and above 60 years old.

Criteria for Assessment:

Subjective Parameters:

Joint Score: The no. of clinically active joints were determined on the basis of tenderness on pressure or painful passive movements.

Score 3 More than 5 joints. Score 2 Joints between 3-5. Score 1 At least 2 joints. Score 0 Less than 2 joints.

Episode of Numbness:

Score 3 Above 60 min. For 30-59 min. Score 2 Score 1 For 0-29 min. Score 0 No numbness

Severity of Pain: (By VAS Scale)

Score 3 Severe Score 2 Moderate Score 1 Mild Score 0 Nil

Tenderness:

Score 3 Severe Score 2 Moderate Score 1 Mild Score 0 Nil

(109) vidyapharma.com

Objective parameters:

Swelling:

Score 3 Severely present Score 2 Markedly present Score 1 Slightly present

Score 0 Absent

Swelling of interphalangeal joints with rings of various diameters to assess increase or decrease in swelling. Swelling of big joints by measuring their circumference.

Local Temperature of affected joints:

Score 3 Severe Score 2 Moderate Score 1 Mild Score 0 Normal

Grip Strength:

Measured by recording the pressure of that patients can exert by squeezing a partially inflated bag (at a starting of 20 mm of Hg) of a standard sphygmomanometer.

Score 3 : Poor (below 40 mm of Hg)

Grouping and Randomization of Patients:-

60 patients of vatarakta were randomly selected and divided by odd –even method into two groups i.e. Group A & Group B of 30 patients each.

Group A had been given trial drug Erandadi kwath.

Group B had been given controlled drug Kaishor guggulu.

	Group A	Group B
Trial drug	Erandadi Kwath	Kaishor Guggulu
Number of Patients	30	30
Age	20 to 60 years	20 to 60 years
Duration of Treatment	3 Months	3 Months
Dose	40 ml (BD)	750 mg 2 tab BD
Anupan	Sukshoshna Jala	Sukshoshna Jala
Follow up	Every 15 th day up to 3 months	Every 15 th day up to 3 months

Score 2 : Moderate (40-140 mm of Hg) Score 1 : Mild (142-280 mm of Hg) Score 0 : Normal (above 282 mm of Hg

Functional Score:

Score 3: Unable to joint movement

Score 2: With the help of other person or device

Score 1: Able to do with difficulty

Score 0: Able to do without any difficulty

Overall Score:

1-8 - Mild - Grade I

9 – 16 - Moderate - Grade II

17 – 24 - Severe - Grade III

Relief of Symptom:

Patient will be assessed during treatment and result will be assesed.

Good Results : No any complaints.

Moderate Results : 2 steps down. Mild Results: 1 steps down.

No Results No change in complaints.

(110) vidyapharma.com

Methods:

पानीयं षोडरागणुं क्षुण्णे दुव्यपलेक्षपेत । मृतपात्रे क्वाथयेत ग्राह्यमष्टमाञावशेषतमं ॥

(शा.सं.म. २/१)

- Mixture of Bharad churna (coarse powder) of all the 6 constituent drugs (each in 1:1 proportion w/w) of the trial formulation.
- > 20 gm of the above mixture coarse powder + 320 mL water (i.e. 1:16 proportion / ratio w/v)
- ➤ Boiling till 1/8th part (by volume i.e. 40 ml) remains
- > Filtration
- > The solid remnants discarded.
- ➤ Per oral administration of the filtered decoction (Kwatha)
- For each & every drug dosage the kwatha/decoction was freshly prepared and given to the patients imedeatly.

Observations And Results

Joint Score :-

	Day-0		Day-90		%	Unpaired	
Joint score	Mean	Sd	Mean	Sd	Relief	t test	P
	score score						
Group-A	2.367	0.5561	1.067	.86	54.9	3.488	<0.0009 HS
Group-B	2.27	.74	1.833	.83	19.4		

Duration of Numbness:-

Duration	Da	Day-0		Day-90		Unpaired t	
of Numbness	Mean score	Sd	Mean score	Sd	% Relief	test	P
Group-A	1.633	0.4901	0.5667	0.7279	66%	2.936	< 0.0048
Group-B	1.6	0.4983	1.067	0.5833	33%		

Severity of Pain:-

Severity of	D	ay-0	Day-90		%	Unpaired t	
Pain	Mean score	Sd	Mean score	Sd	Relief	test	P
Group-A	2.3	0.4661	0.7667	0.4302	66	7.279	<0.0001 HS
Group-B	2.0	0.2626	1.633	0.4901	18		

(111) vidyapharma.com

Tenderness:-

	Day-0		Day	y-90	%	Unpaired t	
Tenderness	Mean score	Sd	Mean score	Sd	Relief	test	P
Group-A	2.167	0.379	0.6667	0.5467	69.2	4.642	<0.0001 HS
Group-B	2.033	0.1826	1.267	0.4498	37		

Swelling:-

Joint	Da	ay-0	Day	y-90		Unpaired t	
score	Mean score	Sd	Mean score	Sd	% Relief	test	P
Group-A	2.1	0.4026	0.7333	0.4498	65	6.757	<0.0001 HS
Group-B	2.033	0.1826	1.567	0.504	23		

Local Temperature :-

Local	Day-0		Day	y-90		Unpaired t	
Temperature	Mean	Sd	Mean	Sd	%	test	P
	score	Su	score	Su	Relief		_
Group-A	2.067	0.4498	0.8333	0.4611	60	2.238	0.0291
Group-B	2.0	0.3714	1.133	0.5713	43		

Grip Strength:-

Grip	Day-0 Day-90			Unpaired t			
Strength	Mean score	Sd	Mean score	Sd	% Relief	test	P
Group-A	0.9	0.3051	0.4	0.4983	55	2.112	0.039
Group-B	0.8667	0.3457	0.6667	0.4795	25		

Functional Score:-

Functional	Da	y-0	Day	y-90		Unpaired t	
Score	Mean score	Sd	Mean score	Sd	% Relief	test	P
Group-A	0.8333	0.379	0.3667	0.4901	56	2.107	
Group-B	0.8667	0.3457	0.6333	0.4901	27		

(112) vidyapharma.com

Total score:-

	Da	Day-0		Day-90			
Total score	Mean score	Sd	Mean score	Sd	% Relief	Unpaired t test	P
	30010		30010				0.0001
Group-A	14.37	1.402	5.4	1.923	62	9.585	< 0.0001
Group-71	14.57	1.402	J. T	1.723	02	7.363	HS
Group-B	13.67	1.516	9.767	1.591	28		

ESR:-

ECD	Da	Day-0		y-60	Unpaired t	р	
ESR	Mean	Sd	Mean	Sd		P	
Group-A	21.5	4.569	16.96	4.358	31.994	<0.001 HS	
Group-B	20.53	3.502	17.93	3.433	16.656	<0.001 HS	

Uric Acid:-

Uric acid	Day-0		Day-60		Unpaired t	р	
Oric acid	Mean	Sd	Mean	Sd		P	
Group-A	7.813	0.758	7.753	0.708	4.539	<0.001 HS	
Group-B	7.65	0.763	7.59	0.741	4.039	<0.001 HS	

Discussion:

Discussion on effect of treatment -

The comparative relief obtained by each therapy on individual group is discussed here. The effects of both drug was assessed on the basis of changes observed in the assessment criteria.

- Joint Pain: -The response in joint pain by Group- A (Erandadi kwath) was (54.9%) Statistically it highly significant was (p<0.001). The response in joint score by Group-B (kaishor guggulu) was (19.4%) obtained Statistically it was significant. (Comparing both group (p<0.001) which is highly Significant result.)
- **Duration of Numbness:** -The response in joint numbness by Group- A (Erandadi kwath) was (66%), while the response in joint numbness

- score by Group-B (Kaishor guggulu) was (33%) obtained. Statistically both were significant (p<0.001). (Comparing both group P value shows Significant result.)
- Severity of Pain The response of pain by Group A (Erandadi kwath) was (66%), while the response in pain by Group B (Kaishor guggulu) was (18%) obtained. Statistically both were highly significant (p<0.001). (Comparing both group (p<0.001) which is highly Significant result.)
- **Tenderness** The response in Tenderness by Group- A (Erandadi kwath) was (69.2%), while the response in Tenderness by Group-B (Kaishor guggulu) was (37%) obtained. Statistically both were highly significant

vidyapharma.com (113)

- (p<0.001). (Comparing both group P value shows significant result.)
- **Swelling** The response in swelling by Group-A (Erandadi kwath) was (65%), while the response in swelling by Group-B (kaishor guggulu) was (23%) obtained. Statistically both were highly significant (p<0.001). (Comparing both group (p<0.001) which is highly Significant result.)
- **Local temperature** The response in local temperature by Group- A (Erandadi kwath) was (60%), while the response in local temperature by Group-B (kaishor guggulu)) was (43%) obtained. Statistically both were **significant** (p<0.001). Comparing both group P value shows Significant result.
- Grip strength The response in grip strength by Group- A (Erandadi kwath) was (55%). Statistically it was **significant** (p<0.001). The response in local temperature by Group-B (kaishor guggulu) was (25%) obtained. Statistically it was significant.
 - Comparing both group P value shows Significant result.
- Functional score- The response in functional score by Group- A (Erandadi kwath) was (56%) Statistically it was **significant**. The response in functional score by Group-B (kaishor guggulu) was (27%) obtained. Statistically it was significant.
 - Comparing both group P value shows Significant result.
- Total score- The response in Total score by Group- A (Erandadi kwath) was (62%) Statistically it was highly significant (p<0.001). The response in Total score by Group-B (kaishor guggulu) was (28%) obtained. Statistically it was highly significant. (Comparing both group (p<0.001) which is highly Significant result.)

- E.S.R.-The response in E.S.R. by Group- A (Erandadi kwath) was (63.9%) Statistically it was highly significant (p<0.001). The response in E.S.R. by Group-B (Kaishor Guggulu) was (27.6%) obtained. Statistically it was **highly significant.** (Comparing both group (p<0.001) which is highly Significant result.)
- Uric Acid- The response in Uric Acid by Group- A (Erandadi kwath) was statistically it was **significant** (p<0.001). The response in Uric Acid by Group-B (Kaishor Guggulu) was obtained. Statistically it was significant (p<0.001). (Comparing both group which is Significant result.)

In this my clinical study project I had treated all patients of both groups with fresh medicine daily up to 3 months. So the results to the patients were very good in all patients. Looking at my previous results assessment, statistical and clinical tables. I found that all the contains of Erandadi Kwath were properly working as I had thought in my mind. So I can definatly says that the Erandadi Kwath drug which has told in Bhaishajy Ratnavali is a very good drug for pacifyint the Vatarakta especially it is a

It required more duration to pacifying the totally 100% Vatarakta disease or it required another supporting medicine along with this drug.

very usefull in destroying the Samprapti of

Vatarakta. But I got in average 60% results in all

subjectives and objectives criteries.

Conclusion:

- The Erandadi Kwath having the definatly pacifying the property of Vatarakta.
- > In comparision to Kaishor Guggulu it has found that Erandadi Kwath is Significant than Kaishor Guggulu to pacifying the Vatarakta Samprapti.
- As etiological study the non-veg diet, alcohol addiction having the grate importance to develop the pathogenesis of Vatarakta than the other etiological factor.

(114) vidyapharma.com

- > On the basis of the statistical result assessment of this study I conclude that the 3 months duration for the treatment is insufficient.
- > Erandadi Kwath and Kaishor Guggulu both drugs working properly without any complication.
- > It has found that Erandadi Kwath having the significant role to reduce the ESR level in the Vatarakta patients.
- > Erandadi Kwath has the siginificant role to reduce the uric acid level into the Vatarakta patients.

References:

- 1. Acharya Vidyadhar Shukla, Prof. Ravidatt Tripathi : Charak Samhita, Vatshonitchikitsa Adhyaya, Chaukhamba Sanskrit Pratishthan: Vol-2: Reprinted 2013: Page No. 730-750.
- 2. Prof. Siddhi Nandan Mishra Bhaisajyaratnavali, Vataraktarogadhikar, Chaukhamba Surbharti Prakashan, Varanasi: Edition2012: Shloka No.12, Page No. 574.

- 3. Vd. Yadunandan Upadhyay: Madhav Nidanam, Vataraktanidan. Chaukhamba Sansthan, Varanasi: Part 1st: 28th Edition: Page No. 450.
- 4. Prof. P. V. Sharma: Dravyaguna Vijnyana, Chaukhamba Academy: Vol-2: Reprint 2006.
- 5. Dr. Ganesh Krushna Garde: Sarth Vagbhat, Vatashonitnidanam. Anmol Prakashan Pune: Edition1991: Page No. 212.
- 6. Kaviraj Ambikadatta Shastri : Sushrut Samhita, Vatvvadhinidan. Chaukhamba Sanskrit Sansthan, Varanasi: Part 1st: Edition 2011: Page No. 295.
- 7. Prof. K. R. Shrikantha Murthy: Sushrut Samhita Vatavyadhinidan, Chaukhamba Orientalia, Varanasi: Reprint Edition 2010: Part 1st Page no. 467: Part 2nd Page no. 63.
- 8. Vd. P. V. Sharma : Charak Samhita, Chaukhamba Orientaliaa, Varanasi: Part 4th: Edition 2012: Page No.216.
- 9. Vd. Yadunandan Upadhyay Ashtang Hrudayam, Chaukhamba Sanskrut Sansthan, Varanasi: 13th Edition: 2000: Page No. 423

(115) vidyapharma.com